SCHEMBL14034127

SCHEMBL14034127

CB(O)N1CCN[C@@H](C(C)(C)O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073196 0.75 BIRC2 (0.36) —
SCHEMBL753889 0.75 BIRC2 (0.36) —
SCHEMBL24721053 0.73 — —
SCHEMBL24952558 0.69 CCR2 (0.33) —
SCHEMBL16440917 0.68 MAPT (0.45) —
SCHEMBL6299912 0.64 — —
SCHEMBL22102118 0.64 — —
SCHEMBL6299911 0.64 — —
SCHEMBL405690 0.62 — —
Hydrochloric Acid SCHEMBL29469830 0.62 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 — — US disclosed
Send feedback